Neurotoxin

Dr. Ran Rubinstein Opens a New Cosmetic Surgery Office Serving Montvale, NJ

Retrieved on: 
Monday, November 20, 2023
PRP, Practitioner, Columbia, New York, Neurotoxin, Patient satisfaction, Anatomy, Surgeon, Patient, Multimedia, Faculty, Rejuvenation, Elective surgery, Teaching, Center of excellence, Filler (linguistics), Breast augmentation, Society, Rhinoplasty, Knowledge, Hair loss, Health, Hospital, Education, Dentistry, Nursing, Medical device, Sculptra

MONTVALE, N.J., Nov. 20, 2023 /PRNewswire-PRWeb/ -- Expanding Reach: New Montvale Office for Dr. Ran Rubinstein

Key Points: 
  • The new Rubinstein Plastic Surgery Center in Montvale, New Jersey, will allow Dr. Rubinstein to reach more patients.
  • Ran Rubinstein
    The opening of the new Rubinstein Plastic Surgery Center location is a significant milestone in Dr. Rubinstein's mission to make premium plastic surgery services accessible to more people.
  • Located at 160 Summit Ave Suite 201, Montvale, NJ 07645, the new office is conveniently accessible to patients in and around the area.
  • Training Future Plastic Surgeons in Montvale, NJ
    Dr. Rubinstein's commitment to the field of plastic surgery extends beyond his office doors.

SKINCEUTICALS ANNOUNCES OPENING OF SKINCEUTICALS SKINLAB™ ASHBURN IN PARTNERSHIP WITH NOVA PLASTIC SURGERY

Retrieved on: 
Monday, October 30, 2023
Ageing, Physician, Strategic management, Skin, Laser, Senior, Acne, Partnership, Neurotoxin, Patient, Filler (linguistics), Dentistry, Beauty salon, Cosmetics, Growth

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of SkinCeuticals SkinLab™ Ashburn by NOVA Plastic Surgery, located in Loudon County, VA, just 30 miles from Washington D.C.

Key Points: 
  • SkinCeuticals and Board-Certified Plastic Surgeon Dr. Fadi Nukta, Provide State-of-the-Art
    NEW YORK, Oct. 30, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of SkinCeuticals SkinLab™ Ashburn by NOVA Plastic Surgery, located in Loudon County, VA, just 30 miles from Washington D.C.
    With the tagline "Great Skin, Made Easy," SkinCeuticals is proud to welcome their first mid-Atlantic location, marking the twelfth addition to the SkinCeuticals SkinLab™ network.
  • Amy Sloan, Senior Vice President of Business Strategy and Growth, notes, "NOVA Plastic Surgery is the leading surgical and aesthetic clinic in Ashburn, offering exceptional care to their patients, aligning with our gold-standard patient experience."
  • She continues, "We first partnered with NOVA Plastic Surgery in 2017 on the opening of the SkinCeuticals Aesthetic Center by NOVA Plastic Surgery, so the SkinCeuticals SkinLab™ Ashburn location marks an expansion of that successful partnership."
  • In partnership with esteemed physicians, SkinCeuticals curated five science-backed signature treatments that deliver professional-grade results with minimal effort and downtime.

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Retrieved on: 
Thursday, October 26, 2023
Cosmetics, Medical Supplies, Retail, Health, Other Health, Pharmaceutical, Biotechnology, Patient, Hubli railway division, FDA, Dermatology, Physician, Invention, Spasticity, Skin, Research, Speech, Torticollis, Dysphagia, AI, Neurotoxin, Muscular system, Death, Fine chemical, Vaccine, Dietary supplement, Pharmaceutical industry

TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

Key Points: 
  • TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.
  • The entrants were then evaluated against a number of key factors, including originality, efficacy, ambition, and impact.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Health, Hospitals, Health Technology, Pharmaceutical, Biotechnology, Stroke, Research, Medicine, AB toxin, Summit, Neurology, Travel, Patient, Therapy, Education, International Material Data System, Merz, DSM-IV codes, Cerebral palsy, Torticollis, Neurotoxin, Spasticity, Hypersalivation, Physician, Nursing

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.

Key Points: 
  • Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.
  • More than 300 international experts in rehabilitation medicine and neurology will attend the event in Berlin from 6–7 October.
  • The “Merz Expert Connect Summit” is the largest global stand-alone event of its scale in the company’s history.
  • The program of the “Merz Expert Connect Summit” features more than 27 lectures by international thought leaders on a variety of relevant topics.

Ventus Respiratory Technologies to Present at Virginia Hazardous Materials Conference

Retrieved on: 
Tuesday, September 19, 2023
Neurotoxin, Brain damage, CE, Partnership, Carcinogen, TR2, Law enforcement, Virginia Association, Canadian Armed Forces, Lead, Emergency management, City centre, Burn, Expo, Newport News, Virginia, PPE, Police, Particulates, Conditional sentence, Virginia Department of Forestry, Conference, Personal protective equipment

Toronto, Ontario & Newport News, VA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Ventus Respiratory Technologies , which has pioneered a new standard of respiratory protection for law enforcement, the armed forces, and first responders, is pleased to announce that its CEO, Arjun Grewal, has been selected to present at the Virginia Hazardous Materials (“HazMat”) Conference .

Key Points: 
  • Toronto, Ontario & Newport News, VA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Ventus Respiratory Technologies , which has pioneered a new standard of respiratory protection for law enforcement, the armed forces, and first responders, is pleased to announce that its CEO, Arjun Grewal, has been selected to present at the Virginia Hazardous Materials (“HazMat”) Conference .
  • The Virginia HazMat Conference is sponsored by The Virginia Association of Hazardous Materials Response Specialists, which operates in partnership with the Virginia Department of Emergency Management (VDEM).
  • The Conference and Expo runs September 19-22, 2023 at the Newport News Marriott at City Center.
  • ONE9 is Canada’s first and only venture capital fund and accelerator focused purely on national security and critical infrastructure technologies.

SKINCEUTICALS ANNOUNCES OPENING OF SKINCEUTICALS SKINLAB™ WINTER PARK IN ORLANDO

Retrieved on: 
Tuesday, September 12, 2023
Neurotoxin, Partnership, Senior, Village, 3D, Oral and maxillofacial surgery, Skin, Ageing, Statistics, Acne, Laser, Patient, Physician, Oral, Growth, Filler (linguistics), Skinlab, ARPM, Winter Park Village, Population growth, Cosmetics, Pharmaceutical industry, Central Florida

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of the brand's eleventh SkinLab location, SkinCeuticals SkinLab™ Winter Park, in the bustling Winter Park Village in the heart of Orlando, Florida. This new location features brand partners Dr. Jeffrey Hartog, dual Board-Certified Plastic, Oral and Maxillofacial Surgeon, as well as managing partners, Michelle Hartog, ARPN, and Elizabeth Pain, ARPM, to fully own and operate SkinCeuticals SkinLab™ Winter Park. As the latest addition to the SkinCeuticals SkinLab™ network, this expansion joins existing locations including St. Helena, CA; Stamford, CT; Houston, TX; Charleston, SC; Palm Desert, CA; Grand Rapids, MI; Scottsdale, AZ; Miami, FL; Santa Monica, CA; and New York, NY.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of the brand's eleventh SkinLab location, SkinCeuticals SkinLab™ Winter Park, in the bustling Winter Park Village in the heart of Orlando, Florida.
  • SkinCeuticals SkinLab™ Winter Park will be the brand's second largest location in the country and combines professional treatments with SkinCeuticals gold-standard-at-home skincare for the ultimate integrated skincare destination.
  • With such substantial growth, SkinCeuticals SkinLab™ Winter Park will provide integrated skincare solutions and establish a strong presence in a thriving region.
  • The SkinCeuticals SkinLab™ Winter Park will welcome visitors beginning August 2023.

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Monday, August 14, 2023
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Neurotoxin, Therapy, Dysphagia, New England Institute of Religious Research, Muscular system, Speech, OLS, Head, Hubli railway division, Headache, Trial of the century, Pain, Spasmodic torticollis, Physician, Patient, The Retreat, Torticollis, ASPEN, Recurrence, Death, Spasticity, Acetylcholine, Pharmaceutical industry

Peter McAllister, M.D., ASPEN investigator and co-founder and medical director of the New England Institute for Neurology and Headache, commented: “As an ASPEN investigator, I am excited to see the approval of a new treatment option to address symptom reemergence prior to retreatment, a common issue for cervical dystonia patients. Currently, patients experience painful and life-limiting symptom recurrence as early as eight to 10 weeks in clinical practice but cannot be re-treated until 12 weeks. DAXXIFY® is the first long-acting neuromodulator that has the potential to address this significant unmet need -- demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.”

Key Points: 
  • In 2017, the U.S. FDA granted orphan drug designation to DAXXIFY® for the treatment of cervical dystonia in adults.
  • Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia,” said Chief Executive Officer Mark J. Foley.
  • “DAXXIFY’s differentiated efficacy, duration and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

ASPS Global Survey Sheds Light on Cosmetic Surgery Practice and Regulation Challenges

Retrieved on: 
Friday, July 28, 2023
Neurotoxin, Advertising, Education, American Society of Plastic Surgeons, GLF, ASPS, Patient, Physician, Knowledge, Key finding attacks, Plastic, Society, Social media, Safety, Dentistry

Arlington Heights, Ill., July 28, 2023 /PRNewswire-PRWeb/ -- The American Society of Plastic Surgeons (ASPS) Global Leadership Forum (GLF) mission is to advance patient education and promote high standards in plastic surgery across the world through international partnerships. Earlier this year, the GLF surveyed plastic surgeons in Latin America, Europe, Africa, Asia and Oceania to assess the current state of cosmetic surgery practice and regulation in their countries and regions.

Key Points: 
  • Arlington Heights, Ill., July 28, 2023 /PRNewswire-PRWeb/ -- The American Society of Plastic Surgeons (ASPS) Global Leadership Forum (GLF) mission is to advance patient education and promote high standards in plastic surgery across the world through international partnerships.
  • Earlier this year, the GLF surveyed plastic surgeons in Latin America, Europe, Africa, Asia and Oceania to assess the current state of cosmetic surgery practice and regulation in their countries and regions.
  • -Many respondents stated they believe there are no restrictions for noncertified plastic surgeons performing cosmetic surgery in their location.
  • ASPS remains dedicated to upholding high standards in plastic surgery nationally and internationally and investing in the education and safety of patients around the globe.

Merz Therapeutics Expands Business with New Nordics Affiliate

Retrieved on: 
Wednesday, June 28, 2023
Biotechnology, Pharmaceutical, Health, Neurotoxin, Blepharospasm, Desitin, Hypersalivation, Patient, Hemifacial spasm, Torticollis, Therapy, Merz, Pharmaceutical industry, Nordic

By taking the strategic decision to establish the new subsidiary in Stockholm, Merz Therapeutics is assuming full control of its business operations in the region, effectively replacing the previous distribution partner Desitin.

Key Points: 
  • By taking the strategic decision to establish the new subsidiary in Stockholm, Merz Therapeutics is assuming full control of its business operations in the region, effectively replacing the previous distribution partner Desitin.
  • By establishing Merz Therapeutics Nordics AB, the company aims to optimize its market presence, better serve patients and customers, and better capitalize on the region's market potential.
  • CEO of Merz Therapeutics, Stefan König, about the company's expansion in the Nordics: "Establishing our presence in the Nordics is a strategic move that will allow us to better serve our patients’ needs in the region.
  • Together, we embark on an exciting journey to enhance patient outcomes throughout Europe," says Marcus Gollub, Head of Region Europe at Merz Therapeutics.

Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Neurotoxin, Injection, AB toxin, Health care, Stroke, Medication, Ankle, Patient, United Kingdom, Therapy, Spasticity, Merz, MHRA, Pharmaceutical industry

“The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve.

Key Points: 
  • “The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve.
  • This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics.
  • John Lambert, Country Manager of Merz Therapeutics UK & Ireland: “This new therapeutic indication supports an extension of the benefit XEOMIN® can bring in the treatment of spasticity.
  • The therapeutic indication is based on trial data from Japan, where XEOMIN® was also approved for treatment of the lower limb region in 2021.